In March, we added 125 citations in DIDB, including 60 in vitro (with 13 articles published in March 2024) and 65 in vivo articles (with 33 articles published in March 2024).
3 NDA/BLAs approved in 2024, including cefepime and enmetazobactam (EXBLIFEP), letibotulimumtoxina (LETYBO), and tislelizumab (TEVIMBRA), were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.